In The Clinic
Volatile Organic Compounds and Esophageal Cancer: Understanding the Implications for Diagnosis and TreatmentSeptember 08, 2017
While utilization of VOCs in the early detection of esophageal cancer has shown promise, future studies should aim at determining which VOCs would be the most specific in diagnosing GI malignancies.
Recent advances in immunotherapy preceded the approval of programmed cell death 1 (PD-1) inhibitors for the treatment of a variety of cancer types.
Isabel Cunningham, MD, advisory board member for CTA, asks Dr Apperley about how to treat patients with CML that cause specialists particular concern.
Although infrequent, malignancy is a cause of upper gastrointestinal bleeding that should be included on the differential diagnosis.
Researchers confirmed that for most patients with melanoma, entry to an adjuvant systemic therapy trial is a preferable first option.
There are key factors to consider when determining the best treatment strategy for pain in patients with cancer.
The placement of an inferior vena cava filter is understudied in patients with cancer and clear guidelines do not exist.
While lower extremity DVTs are the most common, up to 10% of DVTs can occur in upper extremeties in patients with cancer.
Recent research shows that enoxaparin effectively prevents VTE complications in advanced pancreatic cancer without decreasing efficacy of chemotherapy.
Common gastrointestinal symptoms experienced by patients with cancer can vary widely and determining an underlying malignancy can prove difficult.
Researcher found an improvement in aromatase inhibitor-associated arthralgia in both omega-3 fatty acids and placebo treatment.
New treatment modalities are being developed for patients with pancreatic cancer aimed at improving efficacy as well as limiting toxicity.
ABVD and Stanford V treatment regimens show similar efficacy in patients with Hodgkin lymphoma.
Up to 10 percent of ascites diagnoses are related to cancer.
As newer treatment options for peritoneal carcinomatosis are developed, more clinical data is needed to support use in patients with colorectal cancer.
Oncology patients with malnutrition clinically do worse with respect to survival, response to treatment, and adverse events.
Analysis from phase III ENDEAVOR trial showed Kyprolis and dexamethasone superior to Velcade and dexamethasone in relapsed multiple myeloma.
The "antigocoagulation gastrointestinal stress test" could represent a previously under-recognized modality leading to early detection of GI malignancy.
Onset of sorafenib-associated hand-foot skin reactions can be delayed by urea-based cream plus best supportive care in advanced hepatocellular carcinoma.
Chemotherapy can be dosed based on body surface area or body weight, but some studies show up to 40% of obese patients receive lower doses.
Hypercalcemia is one of the most common laboratory abnormalities in patients with cancer, and oncologists should know how to identify and treat it.
Patients with brain cancer are at increased risk of deep vein thrombosis and consequently pulmonary embolism.
Surveillance for cardiotoxicity must be a part of treating patients with monoclonal antibodies.
Underlying malignancy is a potential cause of nonbacterial thrombotic endocarditis, understanding symptoms and treatment options is important.
Fever is a common symptom for patients with cancer who have neutropenia and it is often difficult to determine if they are in infectious in etiology.
Oncology clinicians must balance the cost, benefit, and risk when comparing inpatient versus outpatient care for patients.
Despite promising results, iniparib was found to be ineffective as first-line therapy for patients with metastatic triple-negative breast cancer.
Rolapitant in combination with granisetron and dexamethasone is effective in preventing chemotherapy-induced nausea and vomiting.
New regimen resulted in significantly less chemotherapy-induced nausea and vomiting in multiple myeloma patients.
Patients with NF-1 are up to 4 times more likely to get both benign and malignant neoplasms, in the muscles, skin, and gastrointestinal tract.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Changes in Renal Cell Carcinoma Pathologic Staging and Histologic Grading
- Study Identifies Patients With Breast Cancer Who Don't Benefit From Adjuvant Chemo
- CD19 CAR T-Cell Therapies: "Expect an Evolution"
- Hypofractionated WBI Found Noninferior to Conventionally Fractionated WBI
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified